ESMO 2014

Oncology Meeting Resources

26 Sep - 30 Sep 2014, Madrid, Spain

ESMO 2014 Congress

The theme for ESMO 2014 was ‘Precision Medicine in Cancer Care.’ Whether you are a medical or surgical oncologist or a radiation oncologist, immunologist or pathologist, practising precision medicine means we are all working towards a common goal – improved patient outcomes. For your convenience and due to the large quantity of information coming from the ESMO 2014 congress, we have split the presentations up by main congress topic to allow you to find the information you need more easily.

Here, you will find the abstracts, posters, PDF presentation and webcasts from ESMO 2014 to the extent the presenters have consented to release their contribution or a slightly modified version thereof. Please, note that the publication of these presentations is a courtesy of the originating authors and is for personal educational purposes only.

Drug Index of ESMO 2014 Abstracts

Special Sessions and Tracks

Useful links





Format available

http://oncologypro.esmo.org/Meeting-Resourc...rolled-multicenter-Phase-III-trial-RADIANT-3

AimEVE significantly improved median progression-free survival vs PBO in patients (pts) with pNET by 6.4 months in RADIANT-3 (11.0 vs 4.6 months; HR 0.35, 95% CI 0.27-0.45; p < 0.001).

Date: 27 Sep 2014
Presenter: James Yao
Resources: Abstract, Presentation, Webcast
Topics: Anti-Cancer Agents & Biologic Therapy, Neuroendocrine Cancers

http://oncologypro.esmo.org/Meeting-Resources/ESMO-2014/Invited-discussant-abstract-1132O

Date: 27 Sep 2014
Presenter: Alexandria Phan
Resources: Presentation, Webcast
Topic: Neuroendocrine Cancers

http://oncologypro.esmo.org/Meeting-Resourc...g-of-small-intestinal-neuroendocrine-tumours

AimAberrant DNA methylation is known to play an important role in the pathogenesis of many human cancers, however little is known about its role in small intestinal neuroendocrine tumour (SI NET) development.

Date: 27 Sep 2014
Presenter: Anna Karpathakis
Resources: Abstract, Presentation, Webcast
Topics: Neuroendocrine Cancers, Pathology/Molecular Biology

http://oncologypro.esmo.org/Meeting-Resourc...hase-II-proof-of-concept-study-MetNET1-trial

BackgroundAbnormal PI3K–Akt–mTOR pathway signaling and autocrine activation of the mTOR pathway, mediated through insulin-like growth factor 1 (IGF1), has been implicated in the proliferation of pNET cells.

Date: 27 Sep 2014
Presenter: Filippo De Braud
Resources: Abstract
Topics: Anti-Cancer Agents & Biologic Therapy, Neuroendocrine Cancers, Supportive Care

http://oncologypro.esmo.org/Meeting-Resourc...-Neuroendocrine-Cancer-Alliance-and-Novartis

BackgroundNeuroendocrine tumors (NET) are rare, heterogeneous cancers, not always well understood by the medical community or public. Over the last two decades the incidence of NET has increased and...

Date: 27 Sep 2014
Presenter: Teodora Kolarova
Resources: Abstract
Topics: Neuroendocrine Cancers, Bioethics, Legal, and Economic Issues

http://oncologypro.esmo.org/Meeting-Resourc...Lu-DOTATATE-in-midgut-neuroendocrine-tumours

BackgroundCurrently, there is an unmet medical need for long-term effective treatment of inoperable, gastro-entero-pancreatic neuroendocrine tumours (GEPNETs). Patients having midgut neuroendocrine...

Date: 27 Sep 2014
Presenter: Maribel Lopera Sierra
Resources: Abstract
Topics: Neuroendocrine Cancers, Surgery and/or Radiotherapy of Cancer

http://oncologypro.esmo.org/Meeting-Resourc...itor-therapy-failure-Stage-I-interim-results

AimThe mTOR inhibitor everolimus is approved for the treatment of patients with advanced pNet but resistance can occur. BEZ235 (BEZ) is an oral, dual inhibitor that targets class I PI3K and downstream effectors mTORC1/2.

Date: 27 Sep 2014
Presenter: Nicola Fazio
Resources: Abstract
Topics: Anti-Cancer Agents & Biologic Therapy, Neuroendocrine Cancers

http://oncologypro.esmo.org/Meeting-Resourc...lence-study-vs-OCT-LAR-30-mg-current-vehicle

Aim The synthetic somatostatin analogue OCT has been marketed for more than 25 years and is successfully used for the treatment of acromegaly and symptoms associated with functional gastroenteropancreatic neuroendocrine tumors (GEP-NET).

Date: 27 Sep 2014
Presenter: Severine Sarp
Resources: Abstract
Topics: Neuroendocrine Cancers, Supportive Care

http://oncologypro.esmo.org/Meeting-Resourc...ing-to-ki67-index-A-single-centre-experience

AimPROMID and CLARINET studies showed antitumor activity associated with SSA, respectively Octreotide LAR (Oc) and Lanreotide LAR (La) in low grade GEP-NET. PROMID enrolled ki67 index 10% pts.

Date: 27 Sep 2014
Presenter: Riccardo Marconcini
Resources: Abstract
Topics: Neuroendocrine Cancers, Supportive Care, Translational Research

http://oncologypro.esmo.org/Meeting-Resourc...ing-everolimus-plus-octreotide-LAR-treatment

AimAbnormal PI3K–Akt–mTOR pathway signaling and autocrine activation of the mTOR pathway, mediated through insulin-like growth factor 1 (IGF1), has been implicated in the proliferation of pNET cells.

Date: 27 Sep 2014
Presenter: Sara Pusceddu
Resources: Abstract
Topics: Neuroendocrine Cancers, Cancer in Special Situations